ADAM17 and COVID-19: In this study, we monitored the levels of ACE2, TMPRSS2, IL-17A, ADAM-17, VD, and AP in NPS, serum, and saliva to assess their impact on health status, further supporting the need for multi-biomarker approaches in evaluating COVID-19’s effects on the immune system.